The Clinical Protocol and Data Management component of the Cancer Therapy &Research Center (CTRC) includes the Clinical Trials Office (CTO) and Data and Safety Monitoring Committee (DSMC) activities including the Quality Assurance Division (QAD). The CTO provides central management, research support and oversight functions for the conduct of cancer-related clinical trials at the CTRC. CTO services are available to all members of CTRC engaged in clinical research;however some researchers elect to use research staff within their departments working in concert with CTO to provide umbrella oversight. The major functions of the CTRC CTO are to: Facilitate timely activation and administration of clinical trials, including preparations and communications required for scientific, ethical, operations and logistics reviews Ensure the research team is adequately trained to support each trial Maintain a centralized web-based repository of all protocol specific documents and consents Provide clinical assistance to facilitate the conduct of clinical trials including but not limited to enrollment and verification of patient eligibility, scheduling of appropriate tests, treatments, and assessments Provide data management support for clinical trials The QAD is separate from the CTO to minimize conflicts. Working with the DSMC, the functions of the QAD are to: Ensure that all reports, including reports of serious adverse events and unanticipated problems, are submitted in accordance with appropriate guidelines. Ensure protocol compliance with institutional policies and agreements, state and federal regulations, data accuracy and data integrity through a system of monitoring and quality assurance Provide training and education regarding best practices in conducting clinical trials to investigators and staff.
The Cancer Therapy &Research Center Clinical Trials Office and Quality Assurance Division are committed to providing effective and efficient infrastructure to support the clinical research efforts of the Center.
|Meng, Jia; Lu, Zhiliang; Liu, Hui et al. (2014) A protocol for RNA methylation differential analysis with MeRIP-Seq data and exomePeak R/Bioconductor package. Methods 69:274-81|
|Ghosh, Sagar; Hughes, Daniel; Parma, Dorothy Long et al. (2014) Association of obesity and circulating adipose stromal cells among breast cancer survivors. Mol Biol Rep 41:2907-16|
|Fok, Wilson C; Livi, Carolina; Bokov, Alex et al. (2014) Short-term rapamycin treatment in mice has few effects on the transcriptome of white adipose tissue compared to dietary restriction. Mech Ageing Dev 140:23-9|
|Gong, Jingjing; Muñoz, Amanda R; Chan, Daniel et al. (2014) STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncotarget 5:2529-41|
|Mousavi, Seyed Mohsen; Sundquist, Jan; Hemminki, Kari (2014) Risk of Kaposi sarcoma among immigrants to Sweden. Acta Derm Venereol 94:476-7|
|Morales, Liza D; Casillas Pavón, Edgar A; Shin, Jun Wan et al. (2014) Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling. PLoS One 9:e97104|
|Biswas, Tanuka; Gu, Xiang; Yang, Junhua et al. (2014) Attenuation of TGF-* signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett 346:129-38|
|Ankerst, Donna P; Boeck, Andreas; Freedland, Stephen J et al. (2014) Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 32:185-91|
|Ramirez, Amelie G; Munoz, Edgar; Holden, Alan E C et al. (2014) Incidence of hepatocellular carcinoma in Texas Latinos, 1995-2010: an update. PLoS One 9:e99365|
|Bansal, H; Yihua, Q; Iyer, S P et al. (2014) WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia 28:1171-4|
Showing the most recent 10 out of 616 publications